 | • レポートコード：MRC2305D109 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界の非侵襲的出生前検査（NIPT）市場規模が2021年に5,028.60百万ドル、2022年には5,709.19百万ドルに達し、更に年平均13.71％成長して2027年には10,871.07百万ドルまで拡大すると予測しています。当調査資料は、非侵襲的出生前検査（NIPT）の世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、コンポーネント別分析（ハードウェア、ソフトウェア）、製品別分析（消耗品、器具）、方法別分析（生化学的スクリーニング検査、母体血漿中無細胞DNA検査、母体血液中胎児細胞検査、超音波検出）、用途別分析（微小欠失症候群、トリソミー）、エンドユーザー別分析（診断研究所、病院）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの構成でまとめております。また、当書には、Agilent Technologies, Inc.、Berry Genetics、BGI Group、Eurofins LifeCodexx AG、Hoffmann-La Roche Ltd.、IGENOMIX、Illumina, Inc.、Laboratory Corporation of America Holdings、NATERA, INC.、PerkinElmer Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の非侵襲的出生前検査（NIPT）市場規模：製品別 - 消耗品の市場規模の市場規模 - 器具の市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：方法別 - 生化学的スクリーニング検査の市場規模 - 母体血漿中無細胞DNA検査の市場規模 - 母体血液中胎児細胞検査の市場規模 - 超音波検出の市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：用途別 - 微小欠失症候群における市場規模 - トリソミーにおける市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：エンドユーザー別 - 診断研究所における市場規模 - 病院における市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：地域別 - 南北アメリカの非侵襲的出生前検査（NIPT）市場規模 アメリカの非侵襲的出生前検査（NIPT）市場規模 カナダの非侵襲的出生前検査（NIPT）市場規模 ブラジルの非侵襲的出生前検査（NIPT）市場規模 ... - アジア太平洋の非侵襲的出生前検査（NIPT）市場規模 日本の非侵襲的出生前検査（NIPT）市場規模 中国の非侵襲的出生前検査（NIPT）市場規模 インドの非侵襲的出生前検査（NIPT）市場規模 韓国の非侵襲的出生前検査（NIPT）市場規模 台湾の非侵襲的出生前検査（NIPT）市場規模 ... - ヨーロッパ/中東/アフリカの非侵襲的出生前検査（NIPT）市場規模 イギリスの非侵襲的出生前検査（NIPT）市場規模 ドイツの非侵襲的出生前検査（NIPT）市場規模 フランスの非侵襲的出生前検査（NIPT）市場規模 ロシアの非侵襲的出生前検査（NIPT）市場規模 ... - その他地域の非侵襲的出生前検査（NIPT）市場規模 ・競争状況 ・企業情報 |
The Global Non-invasive Prenatal Testing Market size was estimated at USD 5,028.60 million in 2021 and expected to reach USD 5,709.19 million in 2022, and is projected to grow at a CAGR 13.71% to reach USD 10,871.07 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Non-invasive Prenatal Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Consumables and Instruments. The Consumables is further studied across Assay Kits & Reagents and Disposables. The Instruments is further studied across Microarrays, Next-generation Sequencing Systems, Polymerase Chain Reaction Instruments, and Ultrasound Devices.
Based on Method, the market was studied across Biochemical Screening Tests, Cell-free DNA in Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, and Ultrasound Detection.
Based on Application, the market was studied across Microdeletion Syndrome and Trisomy.
Based on End User, the market was studied across Diagnostic Laboratories and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Non-invasive Prenatal Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-invasive Prenatal Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-invasive Prenatal Testing Market, including Agilent Technologies, Inc., Berry Genetics, BGI Group, Eurofins LifeCodexx AG, Hoffmann-La Roche Ltd., IGENOMIX, Illumina, Inc., Laboratory Corporation of America Holdings, NATERA, INC., and PerkinElmer Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Non-invasive Prenatal Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-invasive Prenatal Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-invasive Prenatal Testing Market?
4. What is the competitive strategic window for opportunities in the Global Non-invasive Prenatal Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Non-invasive Prenatal Testing Market?
6. What is the market share of the leading vendors in the Global Non-invasive Prenatal Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Non-invasive Prenatal Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of chromosomal abnormalities with increasing maternal age
5.1.1.2. Growing preference for non-invasive techniques over invasive methods
5.1.1.3. Improving reimbursement policies for average and low-risk pregnancies
5.1.2. Restraints
5.1.2.1. Dearth of skilled professionals
5.1.3. Opportunities
5.1.3.1. Increasing awareness of NIPT
5.1.3.2. Untapped emerging markets such as China, India, Brazil, and Mexico
5.1.4. Challenges
5.1.4.1. Reliability of test results, especially in obese women
5.2. Cumulative Impact of COVID-19
6. Non-invasive Prenatal Testing Market, by Product
6.1. Introduction
6.2. Consumables
6.3.1. Assay Kits & Reagents
6.3.2. Disposables
6.3. Instruments
6.4.1. Microarrays
6.4.2. Next-generation Sequencing Systems
6.4.3. Polymerase Chain Reaction Instruments
6.4.4. Ultrasound Devices
7. Non-invasive Prenatal Testing Market, by Method
7.1. Introduction
7.2. Biochemical Screening Tests
7.3. Cell-free DNA in Maternal Plasma Tests
7.4. Fetal Cells in Maternal Blood Tests
7.5. Ultrasound Detection
8. Non-invasive Prenatal Testing Market, by Application
8.1. Introduction
8.2. Microdeletion Syndrome
8.3. Trisomy
9. Non-invasive Prenatal Testing Market, by End User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals
10. Americas Non-invasive Prenatal Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Non-invasive Prenatal Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Non-invasive Prenatal Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Agilent Technologies, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Berry Genetics
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. BGI Group
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Eurofins LifeCodexx AG
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Hoffmann-La Roche Ltd.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. IGENOMIX
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Illumina, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Laboratory Corporation of America Holdings
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. NATERA, INC.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. PerkinElmer Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing